Mechanistically, anti–PD-1/PD-L1 agents more commonly induce thyroiditis and pneumonitis, whereas anti–CTLA-4 therapies are particularly associated with hypophysitis and colitis. Here, PDCD1 is linked to thyroid gland disorder.